Stay updated on Expanded Access to Upadacitinib Clinical Trial
Sign up to get notified when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.

Latest updates to the Expanded Access to Upadacitinib Clinical Trial page
- Check4 days agoChange DetectedFooter updated to show Revision: v3.3.3, with HHS Vulnerability Disclosure and Revision: v3.3.2 removed.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision history shows a new entry v3.3.2 and removal of v3.2.0. No substantive study content or eligibility details were changed.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding/operating status notice was removed from the page. No core study information such as eligibility criteria, interventions, or contact details appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check54 days agoChange DetectedThe new screenshot shows minor visual/layout adjustments to the study page, while core study details (conditions, eligibility criteria, and contact information) remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check83 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference8%

- Check90 days agoChange DetectedUpdate: version bumped to v3.1.0 with a new contact phone number 844-663-3742; previous version v3.0.2 removed.SummaryDifference0.2%

Stay in the know with updates to Expanded Access to Upadacitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.